Home/Filings/4/0000899243-21-036767
4//SEC Filing

Stergiopoulos Sotirios 4

Accession 0000899243-21-036767

CIK 0001840439other

Filed

Sep 20, 8:00 PM ET

Accepted

Sep 21, 4:05 PM ET

Size

5.4 KB

Accession

0000899243-21-036767

Insider Transaction Report

Form 4
Period: 2021-09-17
Transactions
  • Purchase

    Common Stock

    2021-09-17$10.96/sh+34,658$379,8524,400,000 total(indirect: See footnote)
Footnotes (2)
  • [F1]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.89 to $11.04. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]These shares are held directly by A2A Pharmaceuticals Inc. Sotirios Stergiopoulos is a member of the Issuer's Board of Directors and an affiliate of A2A Pharmaceuticals Inc. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

Issuer

Biomea Fusion, Inc.

CIK 0001840439

Entity typeother

Related Parties

1
  • filerCIK 0001856641

Filing Metadata

Form type
4
Filed
Sep 20, 8:00 PM ET
Accepted
Sep 21, 4:05 PM ET
Size
5.4 KB